SCHEMBL14740472

SCHEMBL14740472

O=C(O)c1c(-c2cc(F)ccc2Cl)nc2ccncn12

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EIF4E P06730 2/20 0.35
ABL1 P00519 3/20 0.34
KDM4C Q9H3R0 1/20 0.34
KCNK3 O14649 3/20 0.33
KCNK9 Q9NPC2 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
CCR2 P41597 2/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
MAPK13 O15264 1/20 0.32
MAPK12 P53778 1/20 0.32
MAPK11 Q15759 1/20 0.32
MAPK14 Q16539 1/20 0.32
CDC7 O00311 1/20 0.32
DBF4 Q9UBU7 1/20 0.32
AURKA O14965 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14739455 0.89 JAK2 (0.40) EIF4EKDM4CSMN1; SMN2KMT2AALDH1A1
SCHEMBL14739355 0.83 KMT2A (0.41) KMT2AALDH1A1GAAMAPK13MAPK12
SCHEMBL14739693 0.75 ALDH1A1 (0.48) KMT2AALDH1A1GAA
SCHEMBL14740811 0.75 GPBAR1 (0.48) ABL1KCNK3KCNK9SMN1; SMN2ALDH1A1
SCHEMBL14740395 0.72 SLC2A1 (0.47) KMT2AALDH1A1GAA
SCHEMBL14740783 0.72 DPP4 (0.48) SMN1; SMN2KMT2AALDH1A1GAA
SCHEMBL19700228 0.68 LTK (0.43) ABL1KDM4CKMT2AALDH1A1
SCHEMBL14739452 0.68 ALDH1A1 (0.37) SMN1; SMN2KMT2AALDH1A1GAA
SCHEMBL14739556 0.67 CYP1A2 (0.53) SMN1; SMN2KMT2AALDH1A1CDC7DBF4
SCHEMBL14740467 0.66 PDE4B (0.46) ALDH1A1MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9593109-B2 Bicyclic agonists of GPR131 and uses thereof CYMABAY THERAPEUTICS, INC. (US) 2017-03-14 US disclosed
US-20130059845-A1 BICYCLIC AGONISTS OF GPR131 AND USES THEREOF METABOLEX, INC. 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059845-A1 BICYCLIC AGONISTS OF GPR131 AND USES THEREOF GPR119, GPR88, GPR3 EIF4E 3051/4885ABL1 3754/4885KDM4C 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.